SCHEMBL6570260

SCHEMBL6570260

O=C(NN=Cc1cc(Cl)cc(Cl)c1O)c1ccccc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.77
KDM4E B2RXH2 2/20 0.77
MEN1 O00255 2/20 0.77
KMT2A Q03164 2/20 0.77
TDP1 Q9NUW8 2/20 0.77
USP2 O75604 1/20 0.77
MCOLN3 Q8TDD5 1/20 0.77
L3MBTL1 Q9Y468 1/20 0.77
PIK3CG P48736 1/20 0.61
MAPT P10636 4/20 0.61
KDM1A O60341 3/20 0.57
GCGR P47871 1/20 0.57
ATM Q13315 1/20 0.57
SIRT1 Q96EB6 2/20 0.56
ALOX5 P09917 1/20 0.56
PTGS2 P35354 1/20 0.56
ALDH1A1 P00352 1/20 0.55
RAB9A P51151 2/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6570259 1.00 NPC1 (0.77) NPC1KDM4EMEN1KMT2ATDP1
SCHEMBL685119 1.00 NPC1 (0.77) NPC1KDM4EMEN1KMT2ATDP1
SCHEMBL684567 0.92 MEN1 (0.70) NPC1KDM4EMEN1KMT2ATDP1
SCHEMBL684862 0.90 KDM4E (0.79) NPC1KDM4EMEN1KMT2ATDP1
SCHEMBL685159 0.90 NPC1 (0.70) NPC1KDM4EMEN1KMT2ATDP1
SCHEMBL684848 0.88 NPC1 (0.75) NPC1KDM4EMEN1KMT2ATDP1
SCHEMBL684778 0.87 KDM4E (0.74) NPC1KDM4EMEN1KMT2ATDP1
SCHEMBL685144 0.87 MEN1 (0.60) NPC1KDM4EMEN1KMT2ATDP1
SCHEMBL684936 0.87 SIRT1 (0.67) NPC1KDM4EMEN1KMT2ATDP1
SCHEMBL684570 0.87 MEN1 (0.73) NPC1KDM4EMEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US claimed
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US disclosed
EP-1404644-A2 NOVEL HYDRAZONES Arpida AG, (CH) 2004-04-07 EP disclosed
WO-2002070464-A2 HYDRAZONES AND THEIR THERAPEUTIC USE ARPIDA AG (CH) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110963-A1 Novel hydrazones H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HK1, MPO NPC1 785/4885KDM4E 3228/4885MEN1 2514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.